ArticleBritish journal of cancer2026

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.

Aya Elhusseiny Shaaban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.